Mediwound LtdNASDAQ:MDWD
- LAST PRICE16.7600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots16.5500/ 2
- Ask / Lots17.2000/ 1
- Open / Previous Close--- / 16.7600
- Day Range---
- 52 Week Range
- Volume68
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDWD |
|---|---|---|
| 09:32 ET | 705 | 16.81 |
| 09:33 ET | 100 | 16.66 |
| 09:35 ET | 2000 | 16.7956 |
| 10:20 ET | 100 | 16.57 |
| 10:40 ET | 128 | 16.65 |
| 10:54 ET | 1876 | 16.74 |
| 11:00 ET | 400 | 16.7 |
| 11:21 ET | 850 | 16.745 |
| 11:30 ET | 100 | 16.69 |
| 11:41 ET | 2343 | 16.645 |
| 11:56 ET | 200 | 16.62 |
| 11:57 ET | 1080 | 16.63 |
| 12:33 ET | 100 | 16.69 |
| 12:57 ET | 700 | 16.66 |
| 01:22 ET | 100 | 16.73 |
| 01:33 ET | 2377 | 16.74 |
| 02:05 ET | 100 | 16.725 |
| 02:09 ET | 317 | 16.71 |
| 02:12 ET | 200 | 16.7 |
| 02:16 ET | 150 | 16.7388 |
| 02:21 ET | 100 | 16.7 |
| 02:27 ET | 400 | 16.6501 |
| 02:54 ET | 876 | 16.7 |
| 02:59 ET | 100 | 16.66 |
| 03:03 ET | 300 | 16.65 |
| 03:15 ET | 3847 | 16.7 |
| 03:26 ET | 100 | 16.76 |
| 03:39 ET | 100 | 16.735 |
| 03:42 ET | 1420 | 16.81 |
| 03:44 ET | 6667 | 16.765 |
| 03:48 ET | 100 | 16.78 |
| 03:50 ET | 300 | 16.765 |
| 03:55 ET | 200 | 16.77 |
| 04:00 ET | 4403 | 16.76 |
Nov 12, 2024
MediWound to Report Third Quarter 2024 Financial Results, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mediwound Ltd | 180.8M | -7.8x | --- |
TScan Therapeutics Inc | 208.7M | -3.7x | --- |
TriSalus Life Sciences Inc | 129.8M | -2.6x | --- |
Elutia Inc | 152.1M | -2.1x | --- |
Fennec Pharmaceuticals Inc | 129.5M | -47.0x | --- |
Adagene Inc | 100.1M | -3.1x | --- |
Company Information
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Contact Information
- Headquarters
- 42 Hayarkon StreetYAVNE, Israel 8122745
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Nachum Shamir
- Chief Executive Officer, Director
- Ofer Gonen
- Chief Financial Officer
- Hani Luxenburg
- Chief Operating Officer, Chief Commercial Officer
- Shmulik Hess
- Executive Vice President, General Counsel, Corporate Secretary
- Yaron Meyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $180.8M |
|---|---|
Revenue (TTM) | $20.1M |
Shares Outstanding | 10.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-2.16 |
Book Value | $3.43 |
P/E Ratio | -7.8x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -75.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
